• Business Operation

    Currently, the Group has the following products in the market:

     
    Country of origin
    Market
    PRC
    Hong Kong
    Medical application
    Proprietary products
       
    Livaracine®
    PRC
    Heart & other cardiovascular disease
    Yallaferon®
    PRC
    Vira-infected disease
    Slounase®
    PRC
    Shortening bleeding time & reducing loss of blood
    Eyprotor®
    PRC
    Cornea ulcer
    License-in products
       
    Carnitene®
    Italy
    Cardiac disease
    Ferplex®
    Spain
    Sideropenic Anaemias
    Aloxi®
    France
    Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy
    Gelclair®
    Italy
    Mucositis induced by chemo radiotherapy
    Zanidip®
    Italy
    Hypertension
    Dafnegin®
    Italy
     
    Candiadis
    Veloderm®
    Italy
     
    Burns and wounds healing
    Gaslon N®
    Japan
     
    Gastric Ulcer and Gastritis
    Brio PTCA Balloon
    Catheter
    Italy
     
    PTCA treatment for cardiovascular disease
    Hyalofemme®
    Italy
     
    Vaginal dryness of various origin
    Levocarnitine
    Oral Solution
    Italy
     
    Primary and secondary carnitine deficiency
    Remodulin®
    USA
     
    Pulmonary arterial hypertension

    Research & development
    Market focused development
    Expansion through licensing
    Building intellectual property portfolio

    Clinical development
    Established network of opinion leaders in multi-discipline areas
    A clinical development team composed of 15 professionals with
    4 trained physicians
    Local and global trials focus on targeted therapies

    Manufacturing
    Wholly-owned subsidiary Zhaoke Pharmaceutical (Hefei) Co., Ltd located in Hefei, China, comprising 4 GMP-compliant workshops for the production of topical gel, lyophilized powder for injection, small volume parenteral solutions and eye gel

    Regulatory
    5 professionals fully devoted to dossier translation and preparation
    More than 25 years of combined experience

    Sales & marketing
    Extensive network covering every province in the PRC with
    600 partnerships covering all of China, including Hong Kong and Macau.
    250 strong people direct sales force covering 26 cities in China.
    Headquarters in Hong Kong.
    Regional offices in Beijing, Shanghai and Guangzhou

  • Trading Information
    Listed: Main Board of HKEX
    Sector: Pharmaceutical
    Stock code: 950
    Listed date: July 15, 2002 (Transferred from GEM on 14/5/2010)
    Board Lot: 500
    Issued capital: 592,029,343 shares (as at 30/09/2018)
    Market Cap: HK$3,961 million (as at 30/09/2018)
    P/E ratio: 16.99 (as at 30/09/2018)

  • Financial Highlights
    HK$'000
    Year ended 31 December
    Changes
    2017 2016
    Turnover
    1,008,522
    929,821
    + 8.46%
    Gross profit
    682,404
    668,235
    + 2.12%
    Gross profit margin (%)
    67.7%
    71.9%
    - 4.2 ppt
    Profit from operations
    276,828
    298,426
    - 7.24%
    EBITDA
    334,935
    344,154
    - 2.68%
    Profit attributable to shareholders of the Company
    232,559
    252,002
    - 7.72%
    Earnings per share - Basic (HK cents)
    39.38
    42.79
    - 7.97%
    Total Dividend per Share (HK cents) (Interim + Final)
    7.0
    7.9
    - 11.39%

  • Key Indicators


  • Competitive Advantages
    Strong R&D capabilities
       
    Outstanding clinical development capabilities
     
    Strong & experienced team with successful track records:
      ~ 10 studies completed
      ~ 5 ongoing studies
      ~ 4 studies under preparation
       
    Regulatory capabilities for international products
     
    Strong & experienced team with more than 15 years regulatory experience in the PRC
    Possess expertise in clinical pharmacology and other relevant areas
    Successful track records with SFDA as to:
      ~ Import Drug Licenses obtained
      ~ Clinical Study Approvals obtained
       
    Distinguished sales and marketing capabilities with established sales and distribution network in the PRC
     
    A team of more than 200 professional promoters, business development people and medical representives.
    3 management offices in major cities Beijing, Shanghai and Guangzhou plus the Hong Kong headquarters
    An established network of more than 600 local distributors
    Covering more than 5000 hospitals and every province in the PRC
    Successful in portfolio management
    More than 100,000 patients treated monthly
    A win-win partnership between Lee's Pharm and local distributors
       

© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement
Designed by YSD